Advertisement

Panic Disorder

  • David V. Sheehan
  • B. Ashok Raj

Abstract

Panic disorder was first defined by Spitzer, Endicott, and Robbins (1975) in the early editions of their research diagnostic criteria (RDC). It wa’s later included in the Diagnostic and Statistical Manual, third edition (DSM-III), of the American Psychiatric Association (APA, 1980). Whereas the early definition of panic disorder required at least six panic attacks within a 6-week period for a definite diagnosis to be made, the DSM-III modified these criteria to require only three panic attacks within any 3-week period. Each of these attacks was required to have at least 4 of 12 characteristic symptoms. Though the condition itself had existed long before the DSM-III, it was given separate status as a diagnostic entity based on the research findings of Donald Klein (1964, 1967). Klein’s central observation in these papers was that there was a type of anxiety disorder that was particularly sensitive to imipramine, a tricyclic antidepressant. This tricyclic-sensitive anxiety disorder was characterized by spontaneous panic attacks and often failed to respond to minor tranquilizers. Such observations led the DSM-III committee to make a distinction between panic disorder and generalized anxiety disorder. The underlying assumption in making this distinction was that panic disorder is responsive to tricyclic antidepressants and not to minor tranquilizers, whereas generalized anxiety disorder is sensitive to minor tranquilizers but not to tricyclics. This observation was reinforced by a study by McNair and Kahn (1981), which found that imipramine tended to be more effective than chlordiazepoxide in the treatment of agoraphobia. Subsequently, Sheehan (1982a) and Chouinard, Annable, and Fontaine (1982) independently reported that alprazolam, a triazolobenzodiazepine, was effective in the treatment of panic disorder. This finding suggested that benzodiazepines as a class might be effective in the treatment of panic disorder and at the same time offered a treatment for this condition that was quicker, safer, and easier to tolerate than the earlier recommended treatments with tricyclic antidepressants and monoamine oxidase inhibitors. The finding of a quicker and safer treatment for this condition proved to be a significant stimulus to research on this disorder over the following several years and gave rise to the World Wide Panic Project sponsored by the Upjohn Company, from which many new findings and more precise descriptions of panic disorder emerged. Further, Sheehan (1982b) articulated the emerging idea in the panic disorder literature that we should revise our view of panic disorder as a psychological problem in favor of a medical-illness model for this disorder. He suggested that, in contrast to stress-related situational anxiety, panic disorder appears to be associated with biological abnormalities in the central nervous system to which there is a genetic vulnerability. This new view (which was a logical outcome of the earlier work of Klein) had important implications for treatment and research. Attempts to test the strengths and weaknesses of this hypothesis guided much of the research effort in panic disorder in the 1980s.

Keywords

Anxiety Disorder Generalize Anxiety Disorder Panic Disorder Clinical Psychiatry Panic Attack 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders ( 3rd ed.; DSM-III). Washington, DC: Author.Google Scholar
  2. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed. rev.; DSM-III-R). Washington, DC: Author.Google Scholar
  3. Bibb, J. L., and Chambless, D. L. (1986). Behavior Research and Therapy, 24, 49–58.CrossRefGoogle Scholar
  4. Blackwell, B., Marley, E., Price, J., and Taylor, D. (1967). Hypertensive interaction between monoamine oxidase inhibitors and food stuffs. British Journal of Psychiatry, 113, 349–365.PubMedCrossRefGoogle Scholar
  5. Brodsky, L., Zuniger, J. S., Casenas, E. R. et al. (1983). Refractory anxiety: A mashed epileptiform disorder. Psychiatric Journal of the University of Ottawa, 8, 42–45.PubMedGoogle Scholar
  6. Carr, D. B., and Sheehan, D. V. (1984). Panic anxiety: A new biological model. Journal of Clinical Psychiatry, 45, 323–330.PubMedGoogle Scholar
  7. Charney, D. S., Woods, S. W., Goodman, W. K., et al. (1986). Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam and trazodone. Journal of Clinical Psychiatry, 47, 580–586.PubMedGoogle Scholar
  8. Chouinard, G. Annable, L., Fontaine, R., et al. (1982). Alprazolam in the treatment of generalized anxiety and panic disorders: A double blind placebo controlled study. Psychopharmacology, 77, 229–233.PubMedCrossRefGoogle Scholar
  9. Coryell, W., Noyes, R., and Clancy, J. (1982). Excess mortality in panic disorder. Archives of General Psychiatry, 39, 701–703.PubMedCrossRefGoogle Scholar
  10. Crowe, R. R., Noyes, R., Pauls, D. L., and Slymen, D. (1983). A family study of panic disorder. Archives of General Psychiatry, 40, 1065–1069.PubMedCrossRefGoogle Scholar
  11. Crowe, R. R., Noyes, R., Wilson, A. F., Elston, R. C., and Ward, L. J. (1987). A linkage study of panic disorder. Archives of General Psychiatry, 44, 933–937.PubMedCrossRefGoogle Scholar
  12. Darwin, C. (1872). The expressions of the emotions in man and animals. London: J. Murray. Drachman, D. A., and Hart, C. W. (1972). An approach to the dizzy patient. Neurology, 22, 323–334.Google Scholar
  13. Eaton, W. W., and McLeod, J. (1984). Consumption of coffee or tea and symptoms of anxiety. American Journal of Public Health, 74, 66–68.PubMedCrossRefGoogle Scholar
  14. Feighner, J. P. (1982). A double blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry, 43, 103–107.PubMedGoogle Scholar
  15. Fishman, S. M., Sheehan, D. V., and Carr, D. B. (1985). Thyroid indices in panic disorder. Journal of Clinical Psychiatry, 46, 422–423.Google Scholar
  16. Fontaine, R., and Chouinard, G. (1948). Antipanic effect of clonazepam (letter to the editor). American Journal of Psychiatry, 141, 149.Google Scholar
  17. frame, C. L., Turner, S. M., and Jacob, R. G. (1986). Self-exposure treatment of agoraphobia. Behavior Modification, 8, 115–122.CrossRefGoogle Scholar
  18. Freud, S. (1962). On the grounds for detaching a particular syndrome from neurasthenia under the description “Anxiety neurosis.” In J. Strachey (Ed. and Trans.), The standard edition of the complete psychological works of Sigmund Freud (Vol. 3). London: Hogarth Press. (Original work published 1895.)Google Scholar
  19. Frohlich, E. D., Terazi, R. C., and Dustan, H. P. (1969). Hyperdynamic beta-adrenergic circulatory state. Archives of Internal Medicine, 123, 1–7.PubMedCrossRefGoogle Scholar
  20. Ghadirian, A. M., Gauthier, S., and Bertrand, S. (1986). Anxiety attacks in a patient with a right temporal meningioma. Journal of Clinical Psychiatry, 47, 270–271.PubMedGoogle Scholar
  21. Ghosh, A., and Marks, I. M. (1987). Self-treatment of agoraphobia by exposure. Behavior Therapy, 18, 3–16.CrossRefGoogle Scholar
  22. Goldberg, H. L., and Finnerty, R. (1982). Comparison of buspirone in two separate studies. Journal of Clinical Psychiatry, 43, 87–91.PubMedGoogle Scholar
  23. Gorman, J. M., and Martinez, J. M. (1984). Hypoglycemia and panic attacks. American Journal of Psychiatry, 141, 101–102.PubMedGoogle Scholar
  24. Gray, J. A. (1982). The neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system. Oxford: University Press.Google Scholar
  25. Greer, S. (1969). The prognosis of anxiety states. In M. H. Leder (Ed.), Studies of anxiety (pp. 161–157 ). London: Royal Medical Psychological Association.Google Scholar
  26. Griffith, J. D., Jasinski, D. R., Casten, G. P., and McKinney, G. R. (1986). Investigation of the abuse liability of buspirone in alcohol dependent patients. American Journal of Medicine, 80, 30–35.PubMedCrossRefGoogle Scholar
  27. Haft, J. L., and Litterer, W. E., III. (1984). Chewing nifedipine to rapidly treat hypertension. Archives of Internal Medicine, 144, 2357–2359.PubMedCrossRefGoogle Scholar
  28. Harris, E. L., Noyes, R., and Crowe, R. R. (1983). A family study of agoraphobia: A pilot study. Archives of General Psychology, 40, 1061–1064.CrossRefGoogle Scholar
  29. Hartman, R. J., and Geller, J. (1981). Effects of buspirone on conflict behavior of laboratory rats and monkeys. Proceedings of the Western Pharmacological Society, 24, 179–181.Google Scholar
  30. Insel, T. R., Ninan, P. T., and Aloy, J. (1984). A benzodiazepine receptor meditated model of anxiety: Studies in nonhuman primates and clinical implications. Archives of General Psychiatry, 41, 741–750.PubMedCrossRefGoogle Scholar
  31. Jacob, R. G., Moller, M. B., Turner, S. M., et al. ( 1985, December). Otoneurological dysfunction in patients with panic disorder or agoraphobia with panic attacks. Paper presented at the 17th Annual Convention of the World Congress on Behavior Therapy, Washington, DC.Google Scholar
  32. Katemdahl, D. H., and Vandercreek, L. (1983). Hyperthyroidism and panic attacks. Psychosomatic, 24, 491–496.CrossRefGoogle Scholar
  33. Klein, D. F. (1964). Delineation of two drug responsive anxiety syndromes. Psychopharmacologia, 5, 397–408.PubMedCrossRefGoogle Scholar
  34. Klein, D. F. (1967). Importance of psychiatric diagnosis and prediction of clinical drug effects. Archives of General Psychiatry, 16, 118–126.PubMedCrossRefGoogle Scholar
  35. Lader, M. H. (1972). The nature of anxiety. British Journal of Psychiatry, 121, 481.PubMedCrossRefGoogle Scholar
  36. Lesser, I. M., Rubin, R. T., Lydiard, R. B., et al. (1987). Past and current thyroid function in subjects with panic disorder. Journal of Clinical Psychiatry, 48, 473–476.PubMedGoogle Scholar
  37. Liberthson, R., Sheehan, D. V., King, M. E., and Weyman, A. E. (1986). The prevalence of mitral valve prolapse in patients with panic disorder. American Journal of Psychiatry, 143, 511–515.PubMedGoogle Scholar
  38. Lindeman, C. G., Zitrin, C. M., and Klein, D. F. (1984). Thyroid dysfunction in phobic patients. Psychosomatics, 26, 603–606.CrossRefGoogle Scholar
  39. Lustman, P. J., Griffith, L. S., Clouse, E. R., et al. (1986). Psychiatric illness in diabetes mellitus: Relationship to symptoms and glucose control. Journal of Nervous and Mental Disease, 174, 736–742.PubMedCrossRefGoogle Scholar
  40. Manger, W. M., and Gifford, R. W. (1982). Hypertension secondary to pheochromoaton. Bulletin of the New York Academy of Medicine, 58, 139–158.PubMedGoogle Scholar
  41. Marks, I. S. (1969). Fears and phobias. New York: Academic Press.Google Scholar
  42. Marks, I. S., and Lader, M. (1973). Anxiety states (anxiety neurosis: A review). Journal of Nervous and Mental Disease, 156, 3–18.PubMedCrossRefGoogle Scholar
  43. Mattilla, M. J., Aranko, K., and Seppala, T. (1982). Acute effects of buspirone and alcohol on psychomotor skills. Journal of Clinical Psychiatry, 43, 56–60.Google Scholar
  44. Mavissakalian, M., and Michelson, L. (1986). Two year follow-up of exposure and imipramine treatment of agoraphobia. American Journal of Psychiatry, 143, 1106–1112.PubMedGoogle Scholar
  45. Mavissakalian, M., Michelson, L., and Dealy, R. S. (1983). Pharmacological treatment of agoraphobia: Imipramine versus imipramine with programmed practice. British Journal of Psychiatry, 143, 348–355.PubMedCrossRefGoogle Scholar
  46. McNair, D., and Kahn, R. J. (1981). Imipramine compared with the benzodiazepine for agoraphobia. In D. F. Klein and J. G. Rabkin (Eds.), Anxiety: New research and current concepts (pp. 60–79 ). New York: Raven Press.Google Scholar
  47. Moskowitz, H., and Smiley, A. (1982). Effects of chronically administered buspirone and diazepam in driving related skills performance. Journal of Clinical Psychiatry, 34, 45–55.Google Scholar
  48. Pariser, S. F., Jones, B. A., Pinta, E. R. et al. (1979). Panic attacks: Diagnostic evaluations of 17 patients. American Journal of Psychiatry 136, 105–106.PubMedGoogle Scholar
  49. Paul, S. M., and Skolnick, P. (1981). Benzodiazepine receptors and psychopathological states: towards the neurobiology of anxiety. In D. F. Kline and J. Rabkin (Eds.), Anxiety; New research and changing concepts. New York: Raven Press.Google Scholar
  50. Pauls, D. L., Bocher, K. D., Crowe, R. R., and Noyes, R. (1980). A genetic study of panic disorder pedigrees. American Journal of Human Genetics, 32, 639–644.PubMedGoogle Scholar
  51. Popkin, M. K., Callies, H. L., Lentz, R. D., et al. (1988). Prevalence of major depression, simple phobia and other psychiatric disorders in patients with long standing Type 1 diabetes mellitus. Archives of General Psychiatry, 45, 64–68.PubMedCrossRefGoogle Scholar
  52. Rapp, M. S., Thomas, M. R., and Reyes, E. C. (1983). Mega doses of behavior therapy for treatment resistant agoraphobics. Canadian Journal of Psychiatry, 28, 105–109.Google Scholar
  53. Redmond, D. E. (1977). Alterations in the functions of the nucleus locus coeruleus: A possible model for studies of anxiety. In I. Hanin and E. Usdin (Eds.), Animal models in psychiatry and neurology. New York: Pergamon Press.Google Scholar
  54. Reiman, E. M., Raichle, M. E., and Butler, F. K. (1984). PET focal brain abnormality in panic disorder. Nature, 310, 683–685.PubMedCrossRefGoogle Scholar
  55. Riblet, L. A., Eison, A. S., Eison, M. S., Taylor, D. P., Temple, D. L., and VanderMaelen, C. P. (1984). Neuropharmacology of busiprone. Psychopathology, 17, 69–78.PubMedCrossRefGoogle Scholar
  56. Richels, K., Weisman, K., Norstad, N., Singer, M. Stoltz, D., Brown, A., and Danton, J. (1984). Busiprone and diazepam in anxiety. A controlled study. Journal of Clinical Psychiatry, 43, 81–86.Google Scholar
  57. Robins, L. N., Helzer, J. E., and Weissman, M. M. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry, 41, 949–958.PubMedCrossRefGoogle Scholar
  58. Shappiro, S., Skinner, E. A., and Kessler, L. G. (1984). Utilization of health and mental health services. Archives of General Psychiatry, 41, 977.Google Scholar
  59. Sheehan, D. V. (1982). Panic attacks and phobias. New England Journal of Medicine, 307, 156–158.PubMedCrossRefGoogle Scholar
  60. Sheehan, D. V. (1983). The anxiety disease. New York: Scribner’s.Google Scholar
  61. Sheehan, D. V. (1986). Tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics, 27, 10–16.PubMedGoogle Scholar
  62. Sheehan, D. V., and Claycomb, J. B. (1983). The use of MAO inhibitors in clinical practice. In T. C. Manschreck (Ed.), Psychiatric medicine update: Massachusetts General Hospital review for physicians. New York: Elsevier.Google Scholar
  63. Sheehan, D. V., and Sheehan, K. E. (1983). The classification of phobic disorders. International Journal of Psychiatric Medicine, 12, 243–264.CrossRefGoogle Scholar
  64. Sheehan, D. V., Ballenger, J., and Jacobson, G. (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondrical symptoms. Archives of General Psychiatry, 31, 51–59.CrossRefGoogle Scholar
  65. Sheehan, D. V., Sheehan, K. E., and Minichiello, W. E. (1981). Age of onset of phobic disorders: A reevaluation. Comprehensive Psychiatry, 22, 544–553.PubMedCrossRefGoogle Scholar
  66. Sheehan, D. V., Davidson, J., Manschneck, T. C., et al. (1983). Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. Journal of Clinical Psychopharmacology, 3, 28–31.PubMedCrossRefGoogle Scholar
  67. Sheehan, D. V., Claycomb, J. B., Surman, O. S., et al. (1984). The relative efficacy of alprazolam, phenelzine, and imipramine in treating panic attacks and phobias. Annual meeting of the American Psychiatric Association, Los Angeles, May 8.Google Scholar
  68. Sheehan, D. V., Raj, B. A., Soto, S., et al. (1987, May). Is buspirone effective for panic disorders? A double blind placebo controlled study. Paper presented at NCDEU Annual Meeting, Bay Biscayne, FL.Google Scholar
  69. Smith, D. E. (1968). Acute and chronic toxicity of marijuana. Journal of Psychoactive Drugs, 2, 37–47.CrossRefGoogle Scholar
  70. Spier, S. A., Teser, G. E., Rosenbaum, J. F., and Woods, S. W. (1986). Treatment of panic disorder with clonazepam. Journal of Clinical Psychiatry, 47, 238–242.PubMedGoogle Scholar
  71. Spitzer, R. L., Endicott, J., and Robbins, E. (1975). Research diagnostic criteria. New York: New York State Psychiatric Institute, Division of Biometric Research.Google Scholar
  72. Starrman, M. N., Zelnik, T. C., Nesse, R. M., et al. (1958). Anxiety in patients with pheochromocytoma. Archives of Internal Medicine, 145, 248–252.Google Scholar
  73. Strauss, E., Risser, A., and Jones, M. W. (1982). Fear responses in patients with epilepsy. Archives of Neurology, 39, 626–630.PubMedCrossRefGoogle Scholar
  74. Teich, M. J., Agras, W. S., Taylor, C. B., Roth, W. T., and Gallen, C. C. (1958). Combined pharmacological and behavioral treatment for agoraphobia. Behavior Research and Therapy, 23, 325–355.Google Scholar
  75. Tompkins, E. C., Clemento, A. J., Taylor, D. P., and Pemach, J. L. (1980). Inhibition of aggressive behavior in rhesus monkeys by buspirone. Research Communications in Psychology, Psychiatry and Behavior, 5, 337–352.Google Scholar
  76. Torgersen, S. (1983). Genetic factors in anxiety disorders. Archives of General Psychiatry, 40, 1085–1089.PubMedCrossRefGoogle Scholar
  77. Uhde, T. W., Vittone, B. J., and Post, R. M. (1984). Glucose tolerance testing in panic disorder. American Journal of Psychiatry, 141, 1461–1463.PubMedGoogle Scholar
  78. Wall, M., Tuchman, M., and Mielke, D. (1958). Panic attacks and temporal lobe seizures associated with a right temporal lobe arteriovenous malformation: Case report. Journal of Clinical Psychiatry, 46, 145.Google Scholar
  79. Wall, M., Mielke, D., and Luther, J. S. (1986). Panic attacks and psychomotor seizures following right temporal lobectomy. Journal of Clinical Psychiatry, 47, 219.PubMedGoogle Scholar
  80. Watson, A. M., and Gold, M. S. (1948). Chronic cocaine abuse: Evidence for adverse effects on health and functioning. Psychological Annals, 14, 733–745.Google Scholar
  81. Weissman, M. M. (1985). Rates, risks, and familial patterns. In A. H. Tuma and J. D. Maser (Eds.), Anxiety and the anxiety disorders. Hillsdale, NJ: Erlbaum.Google Scholar
  82. Wheatley, D. (1982). Buspirone: Multicenter efficacy study. Journal of Clinical Psychiatry, 43, 92–94.PubMedGoogle Scholar
  83. Wheeler, E. O., White, P. D., Reed, E. W., and Cohen, M. E. (1950). Neurocirculatory asthenia (anxiety neurosis, effort syndrome, neurasthenia): a 20 year follow up study of 173 patients. Journal of the American Medical Association, 142, 878–889.PubMedCrossRefGoogle Scholar
  84. Woodruff, R. H., Guze, S. B., and Clayton, P. J. (1972). Anxiety neurosis among psychiatric outpatients. Comprehensive Psychiatry, 13, 165–170.PubMedCrossRefGoogle Scholar
  85. Zitrin, C. M., Klein, D. F., Woener, M. G., and Rose, D. C. (1983). Treatment of phobias: 1. Comparison of imipramine and placebo. Archives of General Psychiatry, 40, 125–138.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • David V. Sheehan
    • 1
  • B. Ashok Raj
    • 1
  1. 1.Department of Psychiatry and Behavioral MedicineUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations